Passa al contenuto
Merck

Exo1: a new chemical inhibitor of the exocytic pathway.

Proceedings of the National Academy of Sciences of the United States of America (2003-05-10)
Yan Feng, Sidney Yu, Troy K R Lasell, Ashutosh P Jadhav, Eric Macia, Pierre Chardin, Paul Melancon, Michael Roth, Timothy Mitchison, Tomas Kirchhausen
ABSTRACT

A phenotypic screen was used to search for drug-like molecules that can interfere with specific steps in membrane traffic. 2-(4-Fluorobenzoylamino)-benzoic acid methyl ester (Exo1), identified in this screen, induces a rapid collapse of the Golgi to the endoplasmic reticulum, thus acutely inhibiting the traffic emanating from the endoplasmic reticulum. Like Brefeldin A (BFA), Exo1 induces the rapid release of ADP-ribosylation factor (ARF) 1 from Golgi membranes but has less effect on the organization of the trans-Golgi network. Our data indicate that Exo1 acts by a different mechanism from BFA. Unlike BFA, Exo1 does not induce the ADP-ribosylation of CtBP/Bars50 and does not interfere with the activity of guanine nucleotide exchange factors specific for Golgi-based ARFs. Thus, Exo1 allows the fatty acid exchange activity of Bars50 to be distinguished from ARF1 activity in the control of Golgi tubulation.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Exo 1, ≥98% (HPLC), solid